Tesselate Bio is developing precision medicines that target synthetic lethality mechanisms to treat cancers with Homologous Recombination Deficiency (HRD) and other novel interactions. The company focuses on biomarker discovery and companion diagnostics to meet significant unmet needs in cancer therapy, aiming to improve patient outcomes and survival rates.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCFounders
Product
Problem
Many cancers develop resistance to existing therapies, particularly those with Homologous Recombination Deficiency (HRD) and alternative lengthening of telomeres (ALT) mechanisms. There remains a significant unmet need for novel precision medicines and companion diagnostics to improve patient outcomes and survival rates in these cancers.
Solution
Tesselate Bio is developing first-in-class precision medicines that target synthetic lethality mechanisms beyond HRD to treat cancers. The company focuses on identifying novel biological interactions and uncovering new mechanisms to create a pipeline of targeted therapies. By incorporating biomarker discovery and companion diagnostics early in their drug discovery programs, Tesselate Bio aims to personalize cancer treatment and address significant unmet needs in precision oncology.
Target Audience
The primary target audience includes cancer patients with HRD and ALT cancers, as well as oncologists and researchers seeking novel precision medicine approaches.
Features
- Focus on synthetic lethal interactions beyond Homologous Recombination Deficiency (HRD)
- Pipeline of first-in-class precision medicines
- Early incorporation of biomarker discovery in drug development programs
- Development of companion diagnostics (CDx) to personalize treatment
- Targeting cancers with alternative lengthening of telomeres (ALT) mechanisms